Background-Pulmonary hypertension (PH) secondary to left heart failure portends a poor prognosis and is a relative contraindication to heart transplantation at many centers. We tested the hypothesis that when PH persists after adequate left ventricle unloading via recent left ventricular assist device (LVAD) therapy, phosphodiesterase type 5A inhibition would decrease PH in this population.
H eart transplantation is a recognized treatment for endstage heart disease. To ensure the best allocation of this scarce resource, significant risk factors for death after transplantation have been identified including an elevated pulmonary vascular resistance (PVR)Ն3 Wood Units. 1 The International Society for Heart and Lung Transplantation database of 55 359 patients showed a linear relationship between PVR and transplant mortality. 2 Therefore, pulmonary hypertension (PH), measured as increased PVR, has become not only a risk factor for mortality, but a relative contraindication to cardiac transplantation.
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PH from associated left-sided heart failure is thought to result from both a reactive increase in vascular smooth muscle tone as well as a relatively fixed structural remodeling. 3 The former has been shown to be acutely reversible with vasodilators including nitroprusside, 4,5 milrinone, 6 dobutamine, 7 prostaglandin E 1 , 7,8 prostacyclin analogs, 9, 10 and inhaled nitric oxide (NO). 11, 12 The ability to respond to an acute vasodilator challenge has been shown to differentiate groups at high risk of perioperative mortality (those with persistently elevated, "fixed" PVR) from lower risk, transplantable groups. 4, 13, 14 Two small studies have suggested that sildenafil may be useful as a method to test for acute vasodilatory reversibility in heart failure patients. 15, 16 Lewis et al 17 recently demonstrated that a single dose of sildenafil reduced pulmonary artery pressure (PAP) and PVR in patients with PH secondary to New York Heart Association class III heart failure as well as improved peak V02 and exercise performance.
Pulmonary vascular remodeling observed in patients with PH from left-sided heart failure leading to what has been sometimes termed "fixed" or persistent PH and may include medial hypertrophy with or without intimal fibrosis, but a noted absence of plexiform lesions (which are observed in primary PH). 18, 19 These structural changes and lack of acute reversibility may not represent an irreversible abnormality as 80% of patients who underwent a cardiac transplantation despite persistent PH normalized their PVR by 1 year. 20 The precise time course for reversal is unknown, as a more recent study suggests that PVR can normalize as early as 30 days after transplantation. 21 Although the pulmonary vascular remodeling may slowly revert once blood flow has normalized, cardiac transplantation in the setting of an elevated PVR increases the risk of acute right ventricular (RV) failure in the perioperative period.
Several strategies, described in case reports, have attempted to reverse the persistent component of PH to obtain a transplantable PVR value in patients not responsive to acute vasodilatory challenge including long-term prostacyclin administration, 14 cardiac resynchronization therapy, 22 long-term inotropic therapy so-called "vasodilator conditioning" with milrinone or dobutamine, 23 and nesiritide. 24 In addition, small studies report a decrease PVR in persistent PH to a transplantable level after implantation of a left ventricular assist device (LVAD). [25] [26] [27] [28] Importantly, this reversal occurred over 6 weeks to 1 year. 27, 28 In an attempt to augment this process, oral phosphodiesterase type 5A (PDE5A) inhibitor, sildenafil, appeared as a good candidate. In dogs, long-term oral PDE5A inhibitors significantly inhibited the development of PH secondary to heart failure. 29 Furthermore, Jabbour et al recently published a case series of 6 patients with a cardiomyopathy, an elevated pulmonary capillary wedge pressure (PCWP; average 26.3 mm Hg), and an elevated PVR who were treated with sildenafil to allow for transplantation. In most of these patients, a decrease in PVR and transpulmonary gradient was observed and transplantation was performed. 30 Several case reports exist in which long-term oral sildenafil therapy decreased PVR in a patient with an elevated PCWP to a transplantable level. 31, 32 Given its pharmacological properties and success in patients with other clinical profiles, we performed an open-label clinical trial of sildenafil in LVAD recipients and compared them with historical controls. We hypothesized that PDE5A inhibition will decrease PVR when PH persists despite adequate left ventricle unloading.
Methods and Results
Patients A research protocol designed to determine the effects of sildenafil on PAP and PVR was approved by the Johns Hopkins University Institutional Review Board for the open-label use of human subjects. Twenty-six consecutive patients with advanced left ventricular dysfunction, treatment with LVAD implantation, and persistent PH (defined by a PVRϾ3 Wood Units 7 to 14 days after LVAD implantation) despite normalization of their PCWP to a value Ͻ15 mm Hg were consented for and received treatment with sildenafil in an attempt to reduce PVR before cardiac transplantation. Patients with the combined use of LVADs and RVADS were not used. Patients receiving chronic inotrope therapy were excluded from this study. No patients received placebo. Patients in the sildenafil treatment group did not have their angiotensin converting enzyme inhibitor/angiotensin receptor blocker, hydralazine, or ␤-blocker therapy increased after initiation of sildenafil treatment.
For comparison with the sildenafil-treated patients, we reviewed and included all 138 consecutive patients who received LVAD implantation from 1999 to 2007 at our institution. From this group, a total of 58 patients had persistently elevated PVR at the time of subsequent right heart catheterization performed 7 to 14 days post-LVAD implantation of which 26 received sildenafil and 32 did not receive sildenafil. No patients refused sildenafil therapy.
Hemodynamic Measurements
All patients underwent routine right heart catheterization 7 to 14 days (average time, 9.7 days) after the implantation of their LVAD to determine the presence or absence of PVRՆ3 Woods Units and repeated serially at 1-to 3-month intervals after the institution of sildenafil treatment. Patients received no medications by mouth on the morning of subsequent right heart catheterizations. Right heart catheterization was performed as described previously. 6 Cardiac output was determined by thermodilution. Right heart catheterization pressure waveforms data were additionally analyzed for augmentation index (PA ␦P/PP), contractility index (dP/dt max /IP), and isovolumic relaxation time constant (, ms) to determine parameters of pulmonary arterial stiffness, RV systolic function, and RV diastolic function, respectively. This analysis was performed using custom software (WinPVAN, version 3.5.8). Transthoracic echocardiograms were conducted on all patients after right heart catherization to measure tricuspid annular plane systolic excursion (an echocardiographic surrogate of RV systolic function).
Sildenafil Treatment
Patients meeting the above inclusion criteria were started on sildenafil at a dose of 25 mg by mouth 3 times per day with a target dose of 75 mg 3 times a day. The dose was advanced every 2 to 4 days based on tolerability (symptomatic hypotension, gastric reflux, headache, facial flushing) to a final average dose of 51.9Ϯ4.4 mg. All patients tolerated some dose of the medication, and the final dose was achieved in 5 to 7 days. After this initial dose titration, there was no further alteration.
Statistical Analysis
The data are presented as the meanϮSD. A statistical software package (Prism, version 5.01 for Windows; Graphpad Software Inc) was used for the analysis. Continuous variables were compared using the Student t test (unpaired for between-group analyses). Proportions were compared using 2 . The primary end point of the 12 to 15 weeks change in PVR and dP/dt max /IP was analyzed using an unpaired Student t test. All results were tested for 2-sided significance. A probability value Ͻ0.05 was considered to be criterion for statistical significance.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Twenty-six consecutive patients with advanced left ventricular dysfunction, treatment with LVAD implantation, and persistent PH (defined by a PVRϾ3 Wood Units 7 to 14 days after LVAD implantation) despite normalization of PCWP to a value Ͻ15 mm Hg were treated with sildenafil to lower PVR before cardiac transplantation. Thirty-two consecutive LVAD control subjects were identified as outlined above. Table 1 outlines the characteristics of these 2 groups including pre-and post-LVAD medication use. Baseline pre-and post-LVAD hemodynamic values are shown in Table 2 in both groups before open-label treatment with sildenafil. Both groups were similar with regard to pre-and post-LVAD hemodynamics. Figure 1 shows summary data including the influence of LVAD therapy on cardiac output, mean pulmonary arterial pressure, PCWP, and calculated PVR of the entire combined cohort. Despite normalization of PCWP and a significant increase in cardiac output, this cohort of patients had a change in PVR after intervention with LVAD (5.65Ϯ3.00 to 5.39Ϯ1.78 Wood Units) that was not statistically significant (Pϭ0.56; Figure 1 ). The transpulmonary gradient increased significantly from 13.7Ϯ6.9 to 22.8Ϯ7.9 mm Hg (PϽ0.001).
In the 26 patients receiving sildenafil, there was a significant lowering of mean PAP from 36.5Ϯ8.6 to 24.3Ϯ3.6 mm Hg (PϽ0.0001; Figure 2 ) and PVR from 5.87Ϯ1.93 to 2.96Ϯ0.92 Wood Units (mm Hg L Ϫ1 min Ϫ1 ; PϽ0.001; Figure 2 ) after 2 to 4 weeks of therapy. This improvement in PVR was maintained through 12 to 15 weeks after sildenafil initiation ( Figure 3 ). In contrast, in LVAD control patients with similar baseline clinical ( Table 1 ) and hemodynamic parameters, there was not a statistically significant reduction in PVR during the same time period (13 to 17 weeks post-LVAD implantation; Pϭ0.074), although there was a trend toward significance.
In addition to improvements in PVR and transpulmonary gradient, patients treated with sildenafil showed marked improvement in RV systolic and diastolic function, as measured by RV contractility index (dP/dt max /IP; 8.69Ϯ1.78 to 13.1Ϯ3.3; PϽ0.0001) and (91.9Ϯ17.7 to 63.6Ϯ17.8 ms; PϽ0.0001), respectively (Figure 4 ). Pulmonary artery augmentation index was also decreased after sildenafil treatment from 0.195Ϯ0.04 to 0.126Ϯ0.02; PϽ0.0001) and tricuspid annular plane systolic excursion increased from 1.73Ϯ0.21 to 2.00Ϯ0.2 cm (PϽ0.001), suggesting a reduced large artery pulmonary vascular stiffness. The increase in RV dP/dt max /IP in patients that received sildenafil at 2 to 4 weeks was sustained through 12 to 15 weeks.
Treatment with sildenafil did not elevate the PCWP or diminish cardiac output ( Figure 2 ). Furthermore, sildenafil was well tolerated, and there was no increased incidence of arrhythmias (atrial fibrillation, ventricular tachycardia, and ventricular fibrillation) based on bimonthly interrogation of internal cardioverter defibrillators as well as Holter monitoring (data not shown). Four patients experienced facial flushing that occurred immediately after the first 2 doses. Two patients reported gastric reflux that began after the first administered dose and continued until day 3 of treatment with spontaneous resolution. None of these reported events resulted in the alteration of dose or discontinuation of drug therapy until after transplantation. After cardiac transplantation, patients were maintained on sildenafil until their first right heart catheterization, at which time patients' dosing was tapered over the following week.
Of the 26 sildenafil-treated patients, 24 reduced their PVR to below 3 Wood Units, and 19 were deemed transplant 
Discussion
End-stage heart failure is associated with significant mortality. Cardiac transplantation is the treatment of choice. PH as defined by an elevated PVR has consistently been identified as a risk for peritransplant mortality and is a relative contraindication to transplantation at most centers. Among potential cardiac transplant candidates with severe left ventricular systolic dysfunction and subsequent PH, there exists a subset of patients in which traditional vasodilators or LVAD therapy does not acutely lower PVR to a level Ͻ3 Wood Units. In our cohort of patients with persistent PH who failed to improve early after LVAD implantation, addition of PDE5A inhibition with sildenafil along with continued LVAD support substantially and rapidly lowered mean PAP and PVR to levels Ͻ3 Wood Units. Measurements of RV function also showed significant improvement after sildenafil treatment. There were no adverse reactions to the therapy.
Our cohort supports and extends the findings by Alaeddini et al, 16 who showed that sildenafil acutely lowered PVR in ICU patients with left-sided cardiac failure, all of which were already on some type of inotrope or vasodilator therapy and had an elevated PCWP. With regard to its potential to allow for transplantation, it supports and extends to the case report by Gomez-Moreno et al, 31 in which a dilated cardiomyopathy patient with a persistently elevate PVR (from Becker muscular dystrophy) failed dobutamine infusion and was treated with 4 months of sildenafil and later successfully transplanted after lowering PVR to a level considered acceptable for transplantation. Jabbour et al 30 used sildenafil to lower PVR in potential cardiac transplant patients, although these patients had elevated PCWP and also demonstrated a response to nitrates or prostacyclins. Thus, the degree of persistent PH in these patients could not be quantified. Our study suggests that sildenafil may lead to significant hemodynamic improvement in patients with PH from left heart failure unresponsive to LVAD therapy (despite normalization of the PCWP). After initiation of sildenafil, there was a marked reduction in PVR, allowing for potential transplantation at our center. Although previous studies have indicated the PVR will improve with LVAD therapy alone, the time period for improvement is relatively lengthy (6 weeks to 1 year). 27, 28 In our control LVAD patients, PVR began to trend lower by 12 to 15 weeks (13 to 17 weeks post-LVAD implantation) as seen in Figure 4 ; however, these patients still had an average PVRϾ4, a value not yet ideal for transplantation. The decrease in PVR was not statistically significant at this time point. Although previous findings suggest PVR values would continue to decline after persistent unloading of the left ventricle and return of normal pulmonary flow, the time frame to achieve this normalization may be prolonged. In our sildenafil cohort, PVR dropped to a transplantable level by 2 to 4 weeks, and this drop was maintained and sustainable with continued therapy over the next several months. It is possible that PVR was lowered even before this time period since Alaeddini et al witnessed a drop in as little as 4 hours. The ability to lower PVR in such a short time frame allows for the potential of earlier transplantation as well as improved hemodynamics in destination LVAD patients. In fact, Klodell et al 33 recently reported using sildenafil to wean inotropic support and inhaled NO from 10 newly implanted LVAD patients.
In addition to its effect on PVR and PAP, sildenafil treatment combined with LVAD improved several measurements of RV function including RV dP/dt max /IP and ( Figure  4 ). Nagendran et al 34 recently showed that PDE5A is upregulated in hypertrophied human RV and acute inhibition with sildenafil can improve contractility evidenced by an increase in RV dP/dt max . Sildenafil has previously been shown to influence in animal models of heart failure. 35 These findings may suggest that sildenafil can improve RV function through mechanisms other than simply lowering PVR and PAP. The relative contribution to hemodynamic improvement is yet to be elucidated. Sildenafil-treated patients witnessed an improvement in tricuspid annular plane systolic excursion, which has previously be shown to be of significant prognostic value. 36 A decrease in pulmonary arterial stiffness measured by augmentation index was also observed.
PDE5A, the enzyme responsible for catabolism of cGMP in the lung, has previously been shown to be upregulated in animal models of hypoxia induced PH as well as in humans with pulmonary arterial hypertension. 37, 38 Because of the success in lowering PVR with sildenafil (a potent PDE5A inhibitor) in our cohort, it is likely that PDE5A plays an important role in this human disease process, specifically one component of persistent PH in left-sided heart failure. This could be the result of upregulation of PDE5A. Patients with persistent PH are unresponsive to inhaled NO in terms of vasodepressor response. 11, 12 cGMP is the second messenger of the NO vasodilatory cascade. If PDE5A is upregulated to the point where it can immediately catabolize any cGMP produced from the inhaled NO, this may explain the lack of vasodilatory response. If this is true in persistent PH in heart failure, then inhibition of the catabolism of cGMP may allow for pulmonary vasodilatation and subsequent lowering of PVR.
This study has its limitations that must be considered. It is an open-label trial, which uses controls that were not treated with sildenafil before those that received the PDE5A inhibitor. With this in mind, other changes in selection or therapies in addition to the sildenafil may have occurred during the more recent time period. Moreover, the actual timing of the initial PVR drop cannot be determined as the first measure of PVR after initiation of sildenafil therapy did not occur until 2 to 4 weeks. It is possible that other vasodilator therapies such as nesiritide or chronic nitrates may reduce mean PAP and PVR in LVAD patients with persistently elevated PVR. Six patients in our cohort were receiving nitrate/hydralazine combination for afterload reduction in the setting of angiotensin converting enzyme inhibitor/angiotensin receptor blocker intolerance. This group was on nitrate therapy before LVAD implantation as well as afterward. No patients received nesiritide.
Certainly further study is needed to define the role of chronic PDE5A inhibition in the setting of left ventricular dysfunction associated with persistent PH including randomized controlled trials with morbidity and mortality outcomes. Several important questions are yet to be answered, including the timing at which to initiate sildenafil therapy. If PDE5A is upregulated in this disease process, earlier treatment with PDE5A inhibitors might prevent the development of PH as seen in animal models. 29 It is not yet known whether PDE5A inhibition should be started before LVAD therapy.
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